SCHEMBL5206473

SCHEMBL5206473

CC(=O)NC[C@H](O)CO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12070548 1.00
SCHEMBL3459825 1.00
SCHEMBL24462896 0.93 LMNA (0.39)
Iodide SCHEMBL8971179 0.88 HIF1A (0.36)
SCHEMBL13411703 0.87 KDM4E (0.43)
SCHEMBL15374908 0.81 LMNA (0.43)
SCHEMBL15374912 0.81 LMNA (0.43)
SCHEMBL15374906 0.81 LMNA (0.43)
SCHEMBL4778177 0.81 THRB (0.40)
SCHEMBL15835816 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3389783-A1 NOVEL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2018-10-24 EP claimed
WO-2017106062-A1 NOVEL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-06-22 WO claimed
WO-2023072974-A1 TRICYCLIC HETEROCYCLES MERCK PATENT GMBH (DE) 2023-05-04 WO disclosed
WO-2021224291-A1 TRICYCLIC HETEROCYCLES USEFUL AS TEAD BINDERS MERCK PATENT GMBH (DE) 2021-11-11 WO disclosed
US-20210300940-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2021-09-30 US disclosed
US-10745356-B2 Compositions and methods for treating tuberculosis THE BROAD INSTITUTE, INC. (US) 2020-08-18 US disclosed
US-20190284140-A1 COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS THE BROAD INSTITUTE, INC. 2019-09-19 US disclosed
US-10329257-B2 Compositions and methods for treating tuberculosis THE BROAD INSTITUTE, INC. (US) 2019-06-25 US disclosed
WO-2017027768-A1 COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS THE BROAD INSTITUTE, INC. (US) 2017-02-16 WO disclosed
US-20160326111-A1 ARYL SUBSTITUTED INDOLES AND THE USE THEREOF PURDUE PHARMA LP (US) 2016-11-10 US disclosed
WO-2016079710-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2016-05-26 WO disclosed
EP-1380121-B1 PROCESS TO PREPARE OXAZOLIDINONES PHARMACIA & UPJOHN CO LLC (US) 2007-09-26 EP disclosed
US-20070032487-A1 Inhibitors of phosphatidylinositol 3-kinase NOVARTIS AG (CH) 2007-02-08 US disclosed
US-20070032487-A1 Inhibitors of phosphatidylinositol 3-kinase NOVARTIS AG (CH) 2007-02-08 US disclosed
US-7087784-B2 Process to prepare oxazolidinones PHARMACIA & UPJOHN (US) 2006-08-08 US disclosed
US-6887995-B2 Process to prepare oxazolidinones PHARMACIA & UPJOHN COMPANY (US) 2005-05-03 US disclosed
US-20040220407-A1 Process to prepare oxazolidinones PERRAULT WILLIAM R 2004-11-04 US disclosed
EP-1380121-A2 PROCESS TO PREPARE OXAZOLIDINONES PHARMACIA &amp; UPJOHN COMPANY (US) 2004-01-14 EP disclosed
US-20020169312-A1 Process to prepare oxazolidinones PHARMACIA & UPJOHN COMPANY 2002-11-14 US disclosed
WO-2002085849-A2 PROCESS TO PREPARE OXAZOLIDINONES PHARMACIA & UPJOHN COMPANY (US) 2002-10-31 WO disclosed